153 related articles for article (PubMed ID: 32298216)
21. A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
Rolfes L; Pfeuffer S; Ruck T; Windhagen S; Oschlies I; Pavenstädt HJ; Angenendt L; Wiendl H; Krämer J; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31704887
[No Abstract] [Full Text] [Related]
22. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
[TBL] [Abstract][Full Text] [Related]
23. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
Hoffman BM; Zeid NA; Alam U; Caress JB
Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
[TBL] [Abstract][Full Text] [Related]
24. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
[No Abstract] [Full Text] [Related]
25. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.
Bianco A; Mari PV; Larici AR; Lucchini M; Nociti V; Losavio FA; De Fino C; Cicchetti G; Coraci D; Richeldi L; Mirabella M
Mult Scler Relat Disord; 2020 Jan; 37():101450. PubMed ID: 31675637
[TBL] [Abstract][Full Text] [Related]
26. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
Šega-Jazbec S; Barun B; Horvat Ledinek A; Fabekovac V; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2017 Oct; 17():151-153. PubMed ID: 29055450
[TBL] [Abstract][Full Text] [Related]
27. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
28. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report.
Alnahdi MA; Aljarba SI; Al Malik YM
Mult Scler Relat Disord; 2020 Jun; 41():102141. PubMed ID: 32446212
[TBL] [Abstract][Full Text] [Related]
30. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
[No Abstract] [Full Text] [Related]
31. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
33. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.
Croteau D; Flowers C; Kulick CG; Brinker A; Kortepeter CM
Neurology; 2018 May; 90(18):e1548-e1552. PubMed ID: 29602912
[TBL] [Abstract][Full Text] [Related]
34. A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
Vakrakou AG; Tzanetakos D; Valsami S; Grigoriou E; Psarra K; Tzartos J; Anagnostouli M; Andreadou E; Evangelopoulos ME; Koutsis G; Chrysovitsanou C; Gialafos E; Dimitrakopoulos A; Stefanis L; Kilidireas C
BMC Neurol; 2018 Oct; 18(1):178. PubMed ID: 30373566
[TBL] [Abstract][Full Text] [Related]
35. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Phelps R; Winston JA; Wynn D; Habek M; Hartung HP; Havrdová EK; Markowitz GS; Margolin DH; Rodriguez CE; Baker DP; Coles AJ
Mult Scler; 2019 Aug; 25(9):1273-1288. PubMed ID: 30986126
[TBL] [Abstract][Full Text] [Related]
36. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
Nerrant E; Thouvenot E; Castelnovo G
Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519
[No Abstract] [Full Text] [Related]
37. A case of severe Legionella pneumonia following alemtuzumab infusion for multiple sclerosis.
Spurgeon EN; Abbatemarco JR; Miranda C; Rensel MR
Clin Neurol Neurosurg; 2020 Sep; 196():105961. PubMed ID: 32554236
[No Abstract] [Full Text] [Related]
38. Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
Reddel SW; Barnett MH; Riminton S; Dugal T; Buzzard K; Wang CT; Fitzgerald F; Beadnall HN; Erickson D; Gahan D; Wang D; Ackland T; Thompson R
Mult Scler; 2019 Jul; 25(8):1124-1131. PubMed ID: 29911471
[TBL] [Abstract][Full Text] [Related]
39. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
[TBL] [Abstract][Full Text] [Related]
40. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
